Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition
Human Molecular Genetics · 2026
DOI: 10.1093/hmg/ddaf177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2026. Verfasst von Rosa B Thorolfsdottir und 40 weiteren Autor:innen. Beteiligte Einrichtung: Amgen deCODE Genetics, Sturlugata 8, 102 Reykjavik, Iceland. Hauptthemen laut MEDLINE: Adaptor Proteins, Signal Transducing, Cardiovascular Diseases, Bone Morphogenetic Proteins. Die Arbeit nennt 61 Literaturangaben.
Abstract (Originalsprache)
The causal effect of lower plasma sclerostin on cardiovascular disease (CVD) risk has previously been examined with the aim of investigating potential side effects of pharmacological sclerostin inhibition for treatment of osteoporosis. We explored the relationship between plasma sclerostin levels and CVDs and bone phenotypes using Mendelian randomization (MR) and correlation between plasma sclerostin levels and these outcomes. We used variants identified in genome-wide association studies of plasma sclerostin levels in large proteomic datasets from the UK Biobank (Olink) and Iceland (SomaScan) as instruments in two separate MR analyses. These analyses did not provide evidence of association between the effects of sequence variants on plasma sclerostin levels and their effects on CVDs and CVD risk factors (P > 0.05). Several of the instruments had heterogenic effects on bone phenotypes and causal estimates in MR were non-significant (P > 0.05/8). Plasma sclerostin levels correlated positively with coronary artery disease, myocardial infarction and CVD risk factors. Our results do not provide evidence supporting the hypothesis that lower plasma sclerostin levels increase CVD risk and suggest that plasma sclerostin levels are not a good surrogate for pharmacological inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amgen deCODE Genetics, Sturlugata 8, 102 Reykjavik, Iceland.
- Faculty of Medicine, School of Health Sciences, University of Iceland, Vatnsmyrarvegur 16, 101 Reykjavik, Iceland.
- School of Engineering and Natural Sciences, University of Iceland, Saemundargata 2, 102 Reykjavik, Iceland.
- Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.
- Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
- Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
ORCID-Profile: Rosa B Thorolfsdottir, Søren Brunak, Christian Erikstrup, Henrik Ullum, Kirk U Knowlton, Henning Bundgaard, Anna Helgadottir, Kari Stefansson
Zitieren
APA
Thorolfsdottir, R. B., Sveinbjornsson, G., Hjorleifsson Eldjarn, G., Aegisdottir, H. M., Styrkarsdottir, U., Gretarsdottir, S., Steinthorsdottir, V., Tragante, V., Oddsson, A., Stefansdottir, L., Thorleifsson, G., Einarsson, G., Helgason, H., Jonsdottir, A. B., Gudjonsson, S. A., Ferkingstad, E., Brunak, S., Brøns, N., Bundgaard, J. S., …, & DBDS Genomic Consortium (2026). Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddaf177
Vancouver
Thorolfsdottir RB, Sveinbjornsson G, Hjorleifsson Eldjarn G, Aegisdottir HM, Styrkarsdottir U, Gretarsdottir S, et al. Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition. Human Molecular Genetics. 2026. doi:10.1093/hmg/ddaf177
BibTeX
@article{Thorolfsdottir2026,
author = {Thorolfsdottir, Rosa B and Sveinbjornsson, Gardar and Hjorleifsson Eldjarn, Grimur and Aegisdottir, Hildur M and Styrkarsdottir, Unnur and Gretarsdottir, Solveig and Steinthorsdottir, Valgerdur and Tragante, Vinicius and Oddsson, Asmundur and Stefansdottir, Lilja and Thorleifsson, Gudmar and Einarsson, Gudmundur and Helgason, Hannes and Jonsdottir, Andrea B and Gudjonsson, Sigurjon A and Ferkingstad, Egil and Brunak, Søren and Brøns, Nanna and Bundgaard, Johan S and Bruun, Mie T and Erikstrup, Christian and Aagaard, Bitten and Vesterager Pedersen, Ole B and Sibilitz, Kirstine L and Sørensen, Erik and Træholt, Jacob and Ullum, Henrik and Zheng, Chaoqun and Knowlton, Kirk U and Nadauld, Lincoln D and Ostrowski, Sisse R and Bundgaard, Henning and Arnar, David O and Jonsdottir, Ingileif and Helgadottir, Anna and Thorsteinsdottir, Unnur and Holm, Hilma and Sulem, Patrick and Gudbjartsson, Daniel F and Stefansson, Kari and DBDS Genomic Consortium, DBDS Genomic Consortium},
title = {Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition},
journal = {Human Molecular Genetics},
year = {2026},
doi = {10.1093/hmg/ddaf177}
}
EUVIMED